利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

28 条记录 (耗时 0.031 秒)

    Chemical Compounds
    1.
    发明申请
    Chemical Compounds 失效

    公开(公告)号：US20080045591A1

    公开(公告)日：2008-02-21

    申请号：US11773952

    申请日：2007-07-05

    申请人： Daryl Rees ,  Phillip Gunning ,  Antonia Orsi ,  Patrick Howson ,  Paul Barraclough ,  Noelle Callizot

    发明人： Daryl Rees ,  Phillip Gunning ,  Antonia Orsi ,  Patrick Howson ,  Paul Barraclough ,  Noelle Callizot

    IPC分类号： A61K31/12 ,  A23L1/00 ,  A23L1/29 ,  A61P1/00 ,  A61P21/00 ,  A61P37/00 ,  C07C49/00 ,  C07C69/78 ,  C12N5/00 ,  C07C49/15 ,  A61P9/12 ,  A61P29/00 ,  A61P19/02 ,  A61K31/216 ,  A23L2/00

    CPC分类号： A61K31/12 ,  C07C45/455 ,  C07C45/62 ,  C07C45/673 ,  C07C45/68 ,  C07C45/74 ,  C07C49/255 ,  C07C49/577 ,  C07C49/84 ,  C07C69/738 ,  C07C217/22 ,  C07C255/56 ,  C07C2601/02 ,  C07C2601/10 ,  C07C2601/14 ,  C07F7/1804 ,  Y02P20/582

    摘要： Compounds of general formula I: wherein: R1 and R2 are, independently of each other, selected from hydrogen, optionally substituted C1-10alkyl, optionally substituted —CO—(C1-10alkyl), optionally substituted C3-10cycloalkyl, optionally substituted —CO—(C3-10cycloalkyl), optionally substituted C2-10alkenyl, optionally substituted —CO—(C2-10alkenyl), optionally substituted aryl, and optionally substituted —CO-aryl, or R1 and R2 together represent an optionally substituted saturated or unsaturated C1-10alkylidene group, or an optionally substituted saturated or unsaturated C3-10cycloalkylidene group, or R1 and R2 together with the carbon atom to which they are attached represent an optionally substituted saturated or unsaturated organic ring containing 3, 4, 5, 6, 7 or 8 ring carbon atoms and optionally 1, 2 or 3 ring heteroatoms selected from O, N and S; R3, which may be the same as, or different from, either of R1 and R2, is selected from optionally substituted C1-10alkyl, optionally substituted C3-10cycloalkyl, optionally substituted C2-10alkenyl, and optionally substituted aryl; R4, R5 and R6 are, independently of each other, selected from hydrogen, optionally substituted C1-10alkyl, OH, optionally substituted C1-10 alkoxy, halo, optionally substituted aryloxy, optionally substituted (C1-10alkyl)-S(O)n— where n=0, 1 or 2, optionally substituted aryl-S(O)n— where n=0, 1 or 2, or R4 is hydrogen and R5 and R6 together represent an optionally substituted saturated or unsaturated organic chain containing 1, 2, 3, 4, 5, 6 or 7 chain carbon atoms and optionally 1, 2 or 3 chain heteroatoms selected from O, N and S, provided that the chain is at least 3 atoms long; with the proviso that, when R1═R2=hydrogen, then any optionally substituted C1-10alkyl or optionally substituted C2-10alkenyl for R3 must have a branch point at one or more of the α and β positions counted from the carbonyl group (or tautomeric form thereof) to which R3 is attached; or a physiologically acceptable salt, complex or prodrug thereof; are disclosed per se and for use in the treatment or prophylaxis of hypersensitivity, smooth muscle disorders, spasmodic conditions, allergic conditions, inflammatory conditions and/or pain.

    Chemical compounds
    2.
    发明授权
    Chemical compounds 失效

    公开(公告)号：US07589123B2

    公开(公告)日：2009-09-15

    申请号：US11773952

    申请日：2007-07-05

    申请人： Daryl David Rees ,  Phillip James Gunning ,  Antonia Orsi ,  Patrick A. Howson ,  Paul Barraclough ,  Noelle Callizot

    发明人： Daryl David Rees ,  Phillip James Gunning ,  Antonia Orsi ,  Patrick A. Howson ,  Paul Barraclough ,  Noelle Callizot

    IPC分类号： A61K31/12 ,  C07C49/00 ,  C07C69/78

    CPC分类号： A61K31/12 ,  C07C45/455 ,  C07C45/62 ,  C07C45/673 ,  C07C45/68 ,  C07C45/74 ,  C07C49/255 ,  C07C49/577 ,  C07C49/84 ,  C07C69/738 ,  C07C217/22 ,  C07C255/56 ,  C07C2601/02 ,  C07C2601/10 ,  C07C2601/14 ,  C07F7/1804 ,  Y02P20/582

    摘要： Compounds of general formula I: wherein: R1 and R2 are, independently of each other, selected from hydrogen, optionally substituted C1-10alkyl, optionally substituted —CO—(C1-10alkyl), optionally substituted C3-10cycloalkyl, optionally substituted —CO—(C3-10cycloalkyl), optionally substituted C2-10alkenyl, optionally substituted —CO—(C2-10alkenyl), optionally substituted aryl, and optionally substituted —CO-aryl, or R1 and R2 together represent an optionally substituted saturated or unsaturated C1-10alkylidene group, or an optionally substituted saturated or unsaturated C3-10cycloalkylidene group, or R1 and R2 together with the carbon atom to which they are attached represent an optionally substituted saturated or unsaturated organic ring containing 3, 4, 5, 6, 7 or 8 ring carbon atoms and optionally 1, 2 or 3 ring heteroatoms selected from O, N and S; R3, which may be the same as, or different from, either of R1 and R2, is selected from optionally substituted C1-10alkyl, optionally substituted C3-10cycloalkyl, optionally substituted C2-10alkenyl, and optionally substituted aryl; R4, R5 and R6 are, independently of each other, selected from hydrogen, optionally substituted C1-10alkyl, OH, optionally substituted C1-10 alkoxy, halo, optionally substituted aryloxy, optionally substituted (C1-10alkyl)-S(O)n— where n=0, 1 or 2, optionally substituted aryl-S(O)n— where n=0, 1 or 2, or R4 is hydrogen and R5 and R6 together represent an optionally substituted saturated or unsaturated organic chain containing 1, 2, 3, 4, 5, 6 or 7 chain carbon atoms and optionally 1, 2 or 3 chain heteroatoms selected from O, N and S, provided that the chain is at least 3 atoms long; with the proviso that, when R1═R2=hydrogen, then any optionally substituted C1-10alkyl or optionally substituted C2-10alkenyl for R3 must have a branch point at one or more of the α and β positions counted from the carbonyl group (or tautomeric form thereof) to which R3 is attached; or a physiologically acceptable salt, complex or prodrug thereof; are disclosed per se and for use in the treatment or prophylaxis of hypersensitivity, smooth muscle disorders, spasmodic conditions, allergic conditions, inflammatory conditions and/or pain.